ConductScience.org, home

Trial · NCT03139032

Registered outcomes17

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryExploratory Endpoint - Change From Baseline in Endoscopic Improvement/Histologic Healing Using Endoscopy or Flexible ProctosigmoidoscopyWeeks 12Only if there are signs of inflammation at screening another evaluation was planned to be performed at week 12.
PrimaryExploratory Endpoint - Change From Baseline in Level of Fecal CalprotectinWeeks 4, 8, and 12
PrimaryExploratory Endpoint - Change From Baseline in Physician Global Assessments for Active Skin Extra-intestinal Manifestations (EIM) (PG, EN and Psoriasis)Weeks 1, 2, 4, 8, and 12
PrimaryExploratory Endpoint - Change From Baseline in Patient Global Assessments for Active Skin EIMWeeks 1, 2, 4, 8, and 12
PrimaryExploratory Endpoint - Change From Baseline in the Dermatology Life Quality Index ScoreWeeks 1, 2, 4, 8, and 12
PrimaryExploratory Endpoint - Change From Baseline in Inflammatory Bowel Disease Questionnaire ScoreWeeks 2, 4, 8, and 12
PrimaryExploratory Endpoint - Change From Baseline in C-reactive ProteinWeeks 1, 2, 4, 8, 12 and the 2-week follow-up visit
PrimaryExploratory Endpoint - Change From Baseline in Leucocyte CharacterizationWeeks 8 and 12
PrimaryExploratory Endpoint - Change From Baseline in Stool Frequency at Ulcerative Colitis EndpointWeeks 1, 2, 4, 8, and 12
PrimaryExploratory Endpoint - Change From Baseline in Rectal Bleeding at Ulcerative Colitis EndpointWeeks 1, 2, 4, 8, and 12
PrimaryExploratory Endpoint - Change From Baseline in Physicians Global Assessments at Ulcerative Colitis EndpointWeeks 1, 2, 4, 8, and 12
PrimaryExploratory Endpoint - Change From Baseline in Lymphocyte CountsWeeks 1, 2, 4, 8, and 12
PrimaryExploratory Endpoint - Change From Baseline in Disease Activity Score at Crohn's Disease EndpointWeeks 1, 2, 4, 8, and 12
PrimaryExploratory Endpoint - Change From Baseline in Psoriasis Area and Severity Index at Psoriasis EndpointWeeks 1, 2, 4, 8, and 12
PrimaryExploratory Endpoint - Changes in Degree of Immune Cell Infiltration as Assessed From Skin Punch Biopsies (From Healthy Skin and From Target Lesion)Weeks -1, 8, and 12.
PrimaryExploratory Endpoint -Changes in Levels of Cytokine Expression as Assessed From Skin Punch Biopsies (From Healthy Skin and From Target Lesion)Weeks -1, 8 and 12.
OtherSafety Measured by Number of Participants With Adverse Events and Serious Adverse EventsFrom date of first dose of study treatment to the safety follow-up visit, approximately 14 weeks
Planned safety evaluations included clinical laboratory tests (chemistry, hematology, and urinalysis), vital signs (blood pressure, pulse, respiratory rate, and oral temperature), physical examination (assessment of general appearance, skin, head \[eyes, ears, nose and throat\], neck, thyroid, lungs, heart, abdomen, back, lymph nodes, and extremities, and body weight), 12-lead electrocardiograms, adverse event reporting, concomitant medication, and lymphocyte counts.

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03139032/registered